Meet Entera Bio: The $85M Company That Could Solve Big Pharma’s Oral GLP-1 Problem
Sponsored · Market Discovery ContentWith a market cap of just $85M, Entera Bio (NASDAQ: ENTX) may be absurdly cheap in a sector where single oral GLP-1 candidates command billion-dollar valuations – creating a massive value disconnect that and an even greater spotlight following Eli Lily’s latest results (NYSE: LLY)
Eli Lilly’s stock cratered 13% last thursday, erasing nearly $100 billion in market value, after its much-hyped oral weight loss pill orforglipron delivered a disappointing 11.2% weight loss – far below the 15% to 21% achieved by injectable therapies like Wegovy and Zepbound. The results didn’t solve the side effect problem either, with roughly 10% of patients still discontinuing due to adverse reactions.
What makes Lilly’s failure particularly telling is that orforglipron represents a fundamentally different approach than successful GLP-1 therapies. While blockbuster drugs like Ozempic and Wegovy are pure peptides, Lilly’s orforglipron is a small molecule drug targeting GLP-1 receptors. Moreover orfoglipron also underperformed Novo Nordisk’s Rybelsus – the oral GLP-1 (semaglutide) peptide formulation of Wegovy. This exposes something crucial to understanding the current oral GLP-1 race: only three companies in the world have cracked the code for delivering pure GLP-1 peptides orally – Novo Nordisk with their $1.8 billion Emisphere acquisition, Viking Therapeutics with their dual agonist in trials, and a little-known Israeli company called Entera Bio which is developing the first GLP-1/Glucagon peptide as a single daily tablet.
Entera Bio: The Under-the-Radar Player to Watch
While Lilly struggles with its small molecule approach, Entera has been quietly working on solving the pure peptide delivery challenge for years. The Israel-based clinical-stage company developed its N-Tab™ platform specifically to enable oral delivery of large peptide molecules that typically require injection, without altering their chemical form or biological integrity.
Entera was early to recognize the injection challenge in the GLP-1 space. While other companies focused on tweaking proteins with medicinal chemistry approaches or pursuing small molecule approaches, Entera built a platform technology designed to transport therapeutic peptides across biological membranes in their pure, unmodified form.
The company’s validation extends beyond theory. Its most advanced program, EB613, represents the first oral parathyroid hormone therapy for osteoporosis, having successfully met primary and secondary endpoints in Phase 2 trials with 161 patients. This clinical proof-of-concept demonstrates the platform works across different peptides with safety and clinically meaningful benefit.
The OPKO Partnership: Fully Funded GLP-1 Development
In March 2025, Entera formalized a partnership with OPKO Health to develop the world’s first oral dual agonist GLP-1/glucagon peptide. The program combines OPKO’s long-acting oxyntomodulin analog (OPK-88006) with Entera’s N-Tab technology, targeting not just GLP-1 receptors but glucagon receptors as well – potentially delivering enhanced metabolic benefits compared to current single-mechanism drugs.
Critically, this partnership is fully funded. OPKO holds 60% ownership while Entera maintains 40%, with OPKO directly investing in Entera shares at $2.17 each to cover Phase 1 development costs. The companies expect to file an Investigational New Drug application with the FDA in the first half of 2026. Entera’s collaboration with OPKO also extends beyond the obesity market into other high-value therapeutic areas. The company is also developing the first oral GLP-2 tablet for Short Bowel Syndrome which has shown impressive preclinical data.
Preclinical data shows the oral formulation achieved favorable pharmacokinetics and bioavailability, with plasma concentrations and systemic exposure consistent with approved oral GLP-1 therapies. In glucose tolerance tests, the oral dual agonist demonstrated statistically significant reductions in plasma glucose levels compared to placebo.
Analysts expect oral GLP-1s to capture up to $50 billion of the projected $150 billion total GLP-1 market by the early 2030s. For pharmaceutical giants facing the complexity Lilly encountered with orforglipron, acquiring proven oral delivery technology offers a more direct path to market leadership.
Looking Ahead – The Race for Oral GLP-1
The demand for oral GLP-1 is something big-pharma is keenly aware of. Novo Nordisk, the developer of Ozempic and Wegovy, the original GLP-1 ‘gangsters’, recognized this challenge early. In 2020, the Danish pharmaceutical giant paid $1.8 billion to acquire Emisphere Technologies, securing full ownership of the Eligen SNAC technology that enabled Rybelsus, the first oral GLP-1 drug. The deal included $1.35 billion for outstanding shares plus $450 million for royalty obligations, demonstrating the premium companies will pay for validated oral delivery platforms.
Entera Bio, with its N-Tab platform, well funded GLP-1 program through OPKO partnership, and broader clinical pipeline, represents exactly the type of strategic asset that could transform a company’s position in these spaces. The company’s relatively small market capitalization positions it both as a potential bargain for investors, as well as a potentially attractive acquisition target for companies seeking to replicate Novo Nordisk’s Emisphere strategy.
Following Lilly’s orforglipron disappointment, the market may increasingly recognize that the future of oral GLP-1 drugs lies not just with internal development efforts, but with acquiring the specialized companies that are already innovating to solve these complex delivery challenges.
Recent News Highlights from Entera Bio (Live Feed)
Disclaimer & Disclosure: This article is a form of paid promotional content/advertising. The Author, Wall Street Wire, has received compensation from Entera Bio Ltd for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available wallstwire.ai/disclosures. We are not responsible for any price targets or market size figures that may be cited in this article nor do we endorse them, they are quoted based on publicly available news reports and additional price targets or figures may exist that may not have been quoted. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to. This article has was not reviewed or approved by the issuer prior to publication and should not be considered an official communication by it.
The Block Brief
Get the next story before the market does.
Startup funding, venture capital and under-the-radar companies, in your inbox. Free.
